🇺🇸 FDA
Pipeline program

PCAR-019 (anti-CD19 CAR-T cells)

PG-019-001

Phase 2 mab active

Quick answer

PCAR-019 (anti-CD19 CAR-T cells) for Acute Lymphocytic Leukemia is a Phase 2 program (mab) at First Tracks Biotherapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
First Tracks Biotherapeutics
Indication
Acute Lymphocytic Leukemia
Phase
Phase 2
Modality
mab
Status
active

Clinical trials